EUVIMEDEUVIMED entdecken
Open Access · CC BY-ND 4.0

Genetic markers associated with the risk of developing diabetic retinopathy and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes

B. M. Kozak, M. I. Chopei, K. S. Afanasieva, R. L. Skrypnyk

Clinical Endocrinology and Endocrine Surgery · 30.06.2026 · (2) · 63-69

DOI: 10.30978/cees-2026-2-63 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology and Endocrine Surgery, online erschienen am 30.06.2026. Verfasst von B. M. Kozak und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Research into genetic markers associated with the development of complications or comorbidities in patients with type 2 diabetes mellitus (DM) will help improve the diagnosis and prognosis of these conditions. Objective — to investigate the association between polymorphisms in the AKR1B1 (rs759853, rs9640883) and PNPLA3 (rs738409) genes with the risk of developing diabetic retinopathy (DR) and metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus. Materials and methods. The study included 80 patients (35 women and 45 men, mean age — 64.3±7.8 years) with type 2 diabetes and divided them into 4 groups based on the presence or absence of DR and MASLD. The first group consisted of 20 patients without DR and liver pathology, the second group consisted of 20 patients with MASLD the third group consisted of 20 patients with DR, and the fourth group consisted of 20 patients with combined DR and MASLD. Аnalysis of the rs759853 and rs9640883 polymorphisms of the AKR1B1 gene and the rs738409 polymorphism of the PNPLA3 gene in all study patients was performed using quantitative PCR, followed by determination of allele and genotype frequencies and calculation of their association with the onset of DR and MASLD.

Results

In the analysis of both AKR1B1 gene polymorphisms (rs9640883, rs759853), the AG heterozygous genotype was predominant in all four groups. A correlation was found between the GG genotype of the AKR1B1 rs9640883 polymorphism and the risk of developing DR. In addition, an association was established between the A allele of the rs759853 polymorphism and the risk of developing both DR and DR and MASLD simultaneously. At the same time, the homozygous genotype for the A allele was found only in patients in Group 4. The presence of the G allele in the homozygous genotype of this same polymorphism may be interpreted as an indicator of a reduced risk of developing DR. No associations were found between the rs738409 polymorphism of the PNPLA3 gene and DR or MASLD.

Conclusions

A statistically significant association was found between the risk of developing DR and the GG genotype of the rs9640883 polymorphism, as well as the A allele of the rs759853 polymorphism of the AKR1B1 gene in patients with type 2 diabetes. The obtained data confirm the usefulness of determining genetic markers of the AKR1B1 gene in patients with type 2 diabetes for the early diagnosis of DR, especially in the presence of comorbidity with MASLD.

Zitieren

APA

Kozak, B. M., Chopei, M. I., Afanasieva, K. S., & Skrypnyk, R. L. (2026). Genetic markers associated with the risk of developing diabetic retinopathy and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes. Clinical Endocrinology and Endocrine Surgery, 63-69. https://doi.org/10.30978/cees-2026-2-63

Vancouver

Kozak BM, Chopei MI, Afanasieva KS, Skrypnyk RL. Genetic markers associated with the risk of developing diabetic retinopathy and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes. Clinical Endocrinology and Endocrine Surgery. 2026:63-69. doi:10.30978/cees-2026-2-63

BibTeX
@article{Kozak2026,
  author = {Kozak, B. M. and Chopei, M. I. and Afanasieva, K. S. and Skrypnyk, R. L.},
  title = {Genetic markers associated with the risk of developing diabetic retinopathy and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes},
  journal = {Clinical Endocrinology and Endocrine Surgery},
  year = {2026},
  number = {2},
  pages = {63--69},
  doi = {10.30978/cees-2026-2-63}
}
Kostenlos starten →